Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-03-12 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy

Minaldi Elisa , Esposito Gerardo , Giani Carlotta , Valerio Laura , Agate Laura , Molinaro Eleonora , Elisei Rossella

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

ea0056p1154 | Thyroid cancer | ECE2018

Circulating thyroid autoantibodies are more sensitive than fine needle aspiration in detecting metastatic thyroid cancer

Ferrari Federica , Agate Laura , Latrofa Francesco

Introduction: Follow up of differentiated thyroid cancer requires periodic measurements of thyroglobulin (Tg) and Tg autoantibodies (TgAb) and neck ultrasound. Recurrence is suspected in presence of rising levels of Tg and/or TgAb. Positive cytology or detectable Tg in washout of fine needle aspiration (FNA) of neck lymph nodes or 131-I neck uptake confirm the diagnosis of metastatic lymph node.Case report: We report on a 25 year-old Caucasian man, affec...

ea0081p638 | Endocrine-Related Cancer | ECE2022

TKI related adverse events in patients with progressive and metastatic thyroid carcinoma: a retrospective analysis of our experience with cabozantinib during EXAM and EXAMINER clinical trial

Cappagli Virginia , Bottici Valeria , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Vandetanib and Cabozantinib are the only two multitarget tyrosine kinase inhibitors approved for the management of metastatic and progressive medullary thyroid cancer. (MTC) Despite their efficacy in terms of progression free survival prolongation and overall response rate, the drug-related toxicity is still a clinical problem, impairing patient’s quality of life and the compliance to the treatment. We retrospectively evaluate the adverse events (AEs) occurred...

ea0081p472 | Thyroid | ECE2022

Cervical lymph nodes metastases in differentiated thyroid cancer: impact on clinical outcome

Gambale Carla , Matrone Antonio , Contartese Lea , Prete Alessandro , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Cervical lymph node metastases at histology are common findings in differentiated thyroid cancer (DTC); however, their impact on clinical outcome is debated.Material and method: 1332 DTC patients, performed the first 131 I treatment between January 2010 and September 2012 and were divided into 2 groups: absence (Nx/N0) or presence (N1) of lymph node metastases at histology. The latter group was further split in central compartment ...

ea0020oc1.1 | Endocrine Tumours | ECE2009

Optimizing time of prophylactic surgery in ret gene carriers on the basis of serum calcitonin

Elisei Rossella , Romei Cristina , Bottici Valeria , Cosci Barbara , Renzini Guilia , Molinaro Eleonora , Agate Laura , Pinchera Aldo

Multiple endocrine neoplasia type 2 (MEN 2) is characterized by the presence of medullary thyroid cancer (MTC) and other benign pathologies. RET mutations are responsible of this disease and their screening is a very sensitive tool for the identification of gene carriers (GC).Aim of this study was to verify the relevance of the basal and pentagastrin (Pg) stimulated serum calcitonin (CT) in the decision to perform TT in GC. We reviewed data of 65 GC foun...

ea0084ps2-07-62 | Graves’ Disease 1 | ETA2022

Multifocality in sporadic and familiar medullary thyroid cancer: analysis of prevalence and possible predictive roles

Cappagli Virginia , Bottici Valeria , Agate Laura , Molinaro Eleonora , Torregrossa Liborio , Elisei Rossella

Aims: Surgery is the only curative treatment for medullary thyroid cancer (MTC) patients and the gold standard practice is still represented by total thyroidectomy and prophylactic central neck compartment lymphnode dissection. As it happened for differentiated thyroid cancer, in the last years some authors proposed less aggressive and extent surgical modality as hemithyroidectomy and ipsilateral neck compartment dissection in unilateral and solitary sporadic MTC cases. Few st...

ea0049ep1414 | Thyroid (non-cancer) | ECE2017

Significant difference between the prevalence of C cell hyperplasia (CCH) in benign thyroid nodules without histological thyroiditis (HT) and in papillary/follicular thyroid cancers (PTC/FTC) at histology

Pieruzzi Letizia , Molinaro Eleonora , Agate Laura , Bottici Valeria , Torregrossa Liborio , Ugolini Clara , Basolo Fulvio , Vitti Paolo , Elisei Rossella

Background: CCH and serum hypercalcitoninemia (iperCT) can be found in benign thyroid diseases such as thyroiditis and in some cases of papillary (PTC) or follicular (FTC) thyroid microcarcinomas. The question of whether the association with these latter is related to the malignancy of the nodule is still unclear.Aim of the study: To evaluate the difference in the CCH prevalence, at histology, in a series of benign (BTN) and malignant (PTC/FTC) thyroid n...

ea0014p345 | (1) | ECE2007

Characterization of facilitative glucose transporters (GLUT) in human thyroid carcinoma cell lines

Ciampi Raffaele , Vivaldi Agnese , Piampiani Pamela , Agate Laura , Salvadori Piero , Del Guerra Alberto , Pinchera Aldo , Elisei Rossella

18FDG-PET is based on the capability of tumor cells to take up glucose. An increment in expression of the glucose transporter 1 (GLUT1) has been observed in thyroid tumors with poor prognosis but very few data are available about the expression of other glucose transporters in thyroid. Here, we study the expression and function of GLUT isoforms 1, 2, 3, 4, 6, 8, 10, 12 in human thyroid carcinoma cell lines ARO and FRO (anaplastic carcinoma), NPA (poorly-differentiated papillar...

ea0014p363 | (1) | ECE2007

Partial redifferentiation of thyroid carcinoma cell lines treated with decitabine and retinoic acid

Vivaldi Agnese , Fabiola Miasaki , Ciampi Raffaele , Agate Laura , Bottici Valeria , Capodanno Alessandra , Collecchi Paola , Pinchera Aldo , Elisei Rossella

In a previous study we demonstrated that retinoic acid (RA) decreased the growth only of thyroid carcinoma cell lines expressing RA receptor β (RAR β) and that decitabine (5-Aza-CdR) re-induced RARβ expression. The aim of this study was to analyze the effects induced by the combined treatment with RA and 5-Aza-CdR in the same thyroid cancer cell lines.We studied the effect of 5-Aza-CdR 800 nM and RA 1 μM on the expression of thyroid s...

ea0084ps1-03-21 | Thyroid Cancer CLINICAL 1 | ETA2022

Risk of structural recurrence in differentiated thyroid carcinoma (DTC) patients without evidence of disease after initial treatment: insights into risk factors and comparison with american thyroid association guidelines

Contartese Lea , Gambale Carla , Prete Alessandro , Puleo Luciana , Cappagli Virginia , Lorusso Loredana , Agate Laura , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: The last American Thyroid Association guidelines (ATA-2015) defined the risk of structural recurrence in patients with DTC cured after initial treatment and according to the initial histology. However, these data resulted from several studies including different patients with different kinds of treatment. We retrospectively evaluated a large population of patients with DTC, treated and followed in a tertiary referral center, with the aim to characterize the rate of...